This report introduces a Brighton Collaboration (BC) case definition for autoimmune hepatitis (AIH), which has been classified as a priority adverse event of special interest (AESI), as there were possible cases seen following COVID-19 vaccination. The case definition was developed by a group of subject matter and BC process experts to facilitate safety data comparability across pre- and post-licensure clinical trials, as well as pharmacovigilance activities in multiple settings with diverse resources and healthcare access. The usual BC case definition development process was followed in an expedited manner, and took two months to complete, including finalising the manuscript for publication, instead of the usual 1 year development time. It includes a systematic review of the literature and an expert consensus to define levels of diagnostic certainty for AIH, and provides specific guidelines for data collection and analysis. Histology, serological and biochemical tests and exclusion of alternate diagnosis were considered necessary to define the levels of certainty (definitive, probable and possible). AEFI reports of suspected AIH were independently classified by the WG members to test its useability and these classifications were used to finalise the case definition. The document underwent peer review by external AIH experts and a Reference Group of vaccine safety stakeholders in high-, low- and middle-income countries to ensure case definition useability, applicability, and scientific integrity. The expedited process can be replicated for development of other standardised case definitions for priority AESIs for endemics and epidemics. While applicable to cases reported following immunisation, the case definition is independent of lapsed time following vaccination and, as such, can also be used to determine background incidence for vaccinated and unvaccinated control groups in studies of causal association. While use of this case definition is also appropriate for the study of safety of other products including drugs, it is not meant to guide clinical case management.
: Enhancing surveillance for adverse events following immunization remains a key global immunization priority. Many low- and middle-income countries (LMICs) are implementing new vaccines without the comprehensive safety monitoring typically conducted in high-income countries. Since 2017, the Global Immunization Safety Team at the US Centers for Disease Control and Prevention, in collaboration with partners, has supported establishing sentinel surveillance systems during vaccine introductions for safety monitoring in LMICs. Through these experiences, many lessons have been learned regarding project initiation, funding opportunities, standardizing data collection, background rate challenges, site selection considerations, and partner coordination. If vaccine safety is prioritized, sentinel surveillance enhances routine monitoring and generates valuable safety data, strengthening the immunization and regulatory programs. As many countries introduce and manufacture vaccines not previously monitored in high-income countries, lessons from safety monitoring during earlier vaccine introductions must be applied. Sustaining the gains in immunization that were hard-earned over the past decades depends on it.